Synthesis and Properties of Oligodeoxynucleotides Carrying 2-Aminopurine by Eritja Casadellà, Ramón et al.
 The Open Organic Chemistry Journal, 2011, 5, 1-8 1 
 
 1874-0952/11 2011 Bentham Open 
Open Access 
Synthesis and Properties of Oligodeoxynucleotides Carrying 2-Aminopurine 
Carme Fàbrega, Santiago Grijalvo and Ramon Eritja* 
Institute for Research in Biomedicine (IRB Barcelona), Institute for Advanced Chemistry of Catalonia (IQAC), Spanish 
Research Council (CSIC), Networking Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 
Baldiri Reixac 10, E-08028 Barcelona, Spain 
Abstract: The use of benzoyl, isobutyryl and dimethylaminomethylidene groups for the protection of the exocyclic amino 
function of 2-aminopurine during oligonucleotide synthesis has been investigated. Best results in the synthesis were ob-
tained with the monomers of 2-aminopurine protected with the isobutyryl group.  
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INTRODUCTION  
 Oligonucleotides carrying non-natural bases are impor-
tant tools for the determination of the molecular basis of 
mutagenesis. Furthermore, their special properties are used 
for structural determination of nucleic acids and proteins that 
bind nucleic acids [1]. 
 2-Aminopurine (P, Fig. 1), an isomer of adenine in which 
the exocyclic amino group is located at position 2 instead of 
position 6, can form two hydrogen-bonded base pairs with 
thymine which are similar to the Watson-Crick A: T base 
pair [2, 3]. In the 2-aminopurine: thymine base pair, one of 
the hydrogen bonds occurs in the minor groove instead of in 
the major groove. Several groups have taken advantage of 
this difference to characterize DNA-protein interactions [4, 
5] and DNA bending [6, 7]. Due to the fluorescent properties 
of 2-aminopurine, this nucleobase is a useful local probe to 
study enzymes that interact with DNA, such as DNA polym-
erases [8-11], helicases [12] and DNA methylases [13, 14] as 
well as in DNA structural studies [15, 16]. 2-Aminopurine 
can also form base pairs with adenine [17] and cytosine [2, 
15, 18, 19] but not with guanine [20]. The formation of 2-
aminopurine: cytosine base pair results in transition muta-
tions during DNA replication [21, 22]. NMR studies showed 
that 2-aminopurine: cytosine base pair adopts a wobble ge-
ometry at neutral and high pH [18, 19]. 
 The preparation of oligonucleotides carrying 2-
aminopurine was first described by Eritja et al. [20]. In this 
method, 2-aminopurine-2'-deoxyribonucleotide was prepared 
enzymatically from the free base [23], and the amino func-
tion was protected with the isobutyryl (ibu) group by anal-
ogy with 2’-deoxyguanosine (dG) [20]. Afterwards, the syn-
thesis of 2-aminopurine phosphoramidite protected with the 
benzoyl (Bz) group was described starting from dG [24]. In 
this method, dG was protected with the Bz group, converted 
to the 6-hydrazino derivative which was reduced with silver  
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(I) oxide [24]. This method is easily scaled-up and detailed 
protocols have been published [25, 26]. The Bz group was 
also selected for the protection of the 2-amino function dur-
ing the synthesis of oligoribonucleotides containing 2-
aminopurine [27]. The synthesis of the ibu derivative of 2-
aminopurine-2'-deoxyriboside has been described by reduc-
tion of 6-chloroguanosine [28] and thioguanosine [29]. In 
addition, oligodeoxynucleoside methylphosphonates contain-
ing 2-aminopurine have been prepared using the base-labile 
phenoxyacetyl (PAC) group for the protection of the amino 
function of 2-aminopurine [30].  
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Fig. (1). Scheme of the hydrogen-bonding between 2-aminopurine 
and thymine. 
 A major concern for these authors was the high stability 
to ammonia of the Bz-protected derivative of 2-aminopurine, 
produced following the McLaughlin's protocol [28, 30]. In 
this sense, the preparation of the PAC-protected derivative of 
2-aminopurine solved this problem, however implied a long 
synthetic route in which the Bz group is first introduced and 
then removed to allow the introduction of the PAC protect-
ing group [30]. Finally, the preparation of oligonucleotides 
containing 15N-2-aminopurine has been described using 2-
fluoropurine-2'-deoxynucleoside as convertible nucleoside 
[31]. However, this method is difficult to scale-up due to the 
enzymatic preparation of the 2-fluoropurine derivative. 
 In this paper, we describe the preparation of the isobu-
tyryl derivative of 2-aminopurine-2'-deoxyriboside using 
McLaughlin's synthetic route [24] and we compare the use of 
the Bz, ibu and dimethylaminomethylidene (dmf) protecting 
groups for the amino function of 2-aminopurine. 
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RESULTS AND DISCUSSION 
Synthesis of N
2
-Protected Derivatives of 2-Aminopurine-
2'-Deoxyriboside 
 Starting from dG, N2-Bz-2-aminopurine-2'-deoxyriboside 
was prepared as previously described [24-26]. The key step 
in this method was the treatment of a guanine derivative 
which has the hydrazino group at position 6 with silver ox-
ide. The preparation of the 6-hydrazino derivative was per-
formed by the activation of position 6 with the 2,4,6-
triisopropylbenzenesulfonyl (TPS) group, followed by nu-
cleophilic displacement with hydrazine. During these reac-
tions, the 3'- and 5'-hydroxyl groups and the 2-amino group 
were protected with the Bz group. After the silver oxide re-
action 3'-, 5'-benzoate esters were selectively hydrolyzed 
giving the N-2-benzoylated derivative. 
 The N2-Bz derivative was reported to be too stable for 
oligonucleotide synthesis by several authors [28, 30]. For 
this reason, and using a similar reaction scheme, N2-ibu-2-
aminopurine-2'-deoxyriboside was prepared (Fig. 2). All 
reactions went to completion as described for the Bz deriva-
tive, giving a major product that was isolated in good yields. 
NMR data of intermediates was in agreement with the pro-
posed structures. The isobutyryl-protected intermediates 
were stable under the reaction conditions. 
 A similar scheme was applied to commercially available 
5'-O-dimethoxytrityl (DMT)-N2-ibu-dG. In this case, the 
starting material was carrying two of the groups needed for 
oligonucleotide synthesis: the DMT and the ibu groups. Dur-
ing the activation of position 6 with TPS-Cl, the free 3'-
hydroxyl group was protected with the trimethylsilyl group. 
Unfortunately, the presence of the bulky and labile DMT 
group at the 5' position slowed down the reaction, and the 
products were recovered in low yields. Moreover, the ibu 
group was lost during the treatment with silver oxide, due to 
the long time needed for this reaction and, 5'-O-DMT-2-
aminopurine deoxyriboside (5, Fig. 3) was isolated instead of 
the desired 2-aminopurine derivative carrying the DMT and 
the ibu groups. 
 Compound 5 was the starting material for the preparation 
of the 2-aminopurine derivative carrying the dmf group. This 
group has been reported as a protecting group of 2-amino 
function of dG in oligonucleotide synthesis, because it is 
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Fig. (2). Synthetic scheme used for the preparation of isobutyryl protected 2-aminopurine phosphoramidite. 
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more labile than the ibu group [32, 33]. Recently, the phos-
phoramidite derivative of 2-aminopurine carrying the dmf 
group has become commercially available. Treatment of 
compound 5 with dimethylformamide dimethyl acetal 
yielded compound 6, that was treated with succinic anhy-
dride. The resulting hemisuccinate was coupled to controlled 
pore glass functionalized with amino groups. 
Depurination and Stability Studies  
 Protected (Bz, ibu) 2-aminopurine 2'-deoxyriboside de-
rivatives carrying the DMT group at 5' position were succin-
ylated and attached to controlled pore glass supports follow-
ing standard protocols [34]. Stability of the different protect-
ing groups to ammonia was studied by treatment of the dif-
ferent nucleoside supports with concentrated ammonia in 
order to simulate oligonucleotide synthesis conditions. Prior 
to ammonia treatment the supports were treated with a 3% 
trichloroacetic acid (TCA) solution to eliminate the 5'-DMT 
group. Thereafter, the supports were treated with concen-
trated ammonia solution at room temperature for one hour to 
hydrolyze the succinyl linkage and the supports were filtered 
out. The solutions were left at room temperature and 55 ºC 
for one day. The study of the efficiency of the removal of 
protecting groups was followed by analytical HPLC. The 
dmf group was found to be the most labile protecting group, 
followed by the ibu group. Both groups can be removed at 
room temperature although the dmf group was totally re-
moved in 2 hours, while the ibu group needed 8 hours. At the 
standard oligonucleotide deprotection conditions (55 ºC, 
minimum 6 hours) both ibu and dmf groups are completely 
removed. Finally, the Bz group was the most stable group, 
although it may be removed at 55 ºC if the deprotection time 
is extended to 1 or 2 days. However, at room temperature the 
Bz group was removed very slowly (20% in 24 hr). 
 Another important parameter in the evaluation of pro-
tected nucleosides for oligonucleotide synthesis is the stabil-
ity to depurination during the removal of the dimethoxytrityl 
group. Previous studies have indicated that this side reaction 
may be important with 2-aminopurine derivatives [20]. In 
order to analyze the extent of the depurination reaction, the 
dinucleotide containing protected 2-aminopurine 5’-TP-3’ 
was prepared using the supports carrying compounds 3 (ibu) 
and 5 (dmf). Dinucleotide supports were treated with a 3% 
TCA solution in dichloromethane during different times (up 
to 7 days) and then the resulting supports were treated with 
concentrated ammonia. Reverse-phase HPLC showed the 
appearance of a side product that was characterized by UV 
spectrometry, enzyme digestion and mass spectrometry as 
the depurination product. This product was quantified in 
relation with the dinucleotide containing 2-aminopurine by 
reading the UV absorption at 260 nm. The dinucleotide car-
rying dmf-protected 2-aminopurine was found to be more 
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Fig. (3). Synthetic scheme used for the preparation of the solid support carrying dimethylformamidine protected 2-aminopurine. 
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sensitive to depurination (half-life ?2 days) than the 
dinucleotide containing ibu-protected 2-aminopurine (38% 
depurination after 7 days). These results allowed us to con-
clude that the dmf group is easier to remove, but, oligonu-
cleotides containing 2-aminopurine with the ibu group are at 
least 4 times more stable to depurination than oligonucleo-
tides carrying 2-aminopurine with the dmf group. 
Oligonucleotide Synthesis 
 A series of self-complementary dodecamers carrying 2-
aminopurine (P) residues P/C: (5’-CGC PAA TTC GCC-3’); 
P/A: (5’-CGC PAA TTA GCC-3’); P/T: (5’-CGC PAA TTT 
GCC-3’); and C/P: (5’-CGC CAA TTP GCC-3’) were pre-
pared using the ibu-protected 2-aminopurine phosphoramid-
ite derivatives, and the appropriate supports. In all cases, 
oligonucleotides were obtained in good yields. In addition, 
the performance of dmf and ibu-protected 2-aminopurine 
phosphoramidites during oligonucleotide synthesis condi-
tions was analyzed for large-scale syntheses of a short se-
quence containing 2-aminopurine. Sequence A (5’-CGT 
AGP GAT GC-3’) was prepared twice on 10 μmol-scale. In 
the first synthesis, ibu-protected 2-aminopurine phosphora-
midite (4) was used and in the second synthesis, dmf-
protected 2-aminopurine phosphoramidite from commercial 
sources was used. Coupling efficiencies were similar for 
both syntheses (99% per step). The last DMT group was left 
during ammonia deprotection in order to use the hydropho-
bicity of this group to isolate the full-length sequence from 
truncated sequences by reversed phase HPLC. After the first 
HPLC purification, a difference in the amount of full-length 
oligonucleotide was obtained. Using ibu-protected phos-
phoramidite, 363 optical density (OD) units at 260 nm (ap-
prox. 3.6 μmol) of DMT-oligonucleotide were obtained; 
while using dmf-protected phosphoramidite, 156 OD units at 
260 nm (approx. 1.6 μmol) of the desired sequence were 
isolated. Moreover, an extra peak after the one of the desired 
DMT-oligonucleotide was observed only in the HPLC puri-
fication coming from the synthesis where dmf-protected 2-
aminopurine phosphoramidite was used. These differences 
could be assigned to 2-aminopurine depurination taking into 
account the higher sensitivity of the dmf-protected 2-
aminopurine derivative to acids described above. Neverthe-
less, some other side reactions such as premature cleavage of 
the dmf group or modification of protected 2-aminopurine 
during capping conditions or iodine oxidation may occur. 
Overall, the use of the ibu group for the protection of the 2-
aminopurine seems advantageous for large scale synthesis. 
 Thermal denaturation of duplexes, containing self-
complementary sequences, were studied in 0.1 M phosphate 
buffer at different pH. In all cases a clear cooperative curve 
was observed. Melting temperatures are shown in Table 1. 
The most stable duplex contained 2-aminopurine: T base 
pairs. At acidic pH, duplexes carrying 2-aminopurine: C base 
pairs are more stable than duplexes carrying 2-aminopurine: 
A base pairs. At neutral pH, duplexes carrying 2-
aminopurine: C and 2-aminopurine: A mismatches have 
similar stability in agreement with published data [20, 35]. 
CONCLUSIONS 
 In summary, we report the preparation of the phosphora-
midite derivative of 2-aminopurine 2'-deoxyriboside pro-
tected with the ibu group, applying a route previously de-
scribed for the Bz derivative [24]. This derivative was con-
veniently deprotected during standard deprotection condi-
tions and is stable to depurination under oligonucleotide syn-
thesis conditions. Alternatively, the dmf group was found to 
be more labile to ammonia but also more susceptible to de-
purination. Nevertheless, the extent of depurination of the 
dmf derivative during normal oligonucleotide synthesis con-
ditions is small and this protecting group is a good alterna-
tive for the protection of 2-aminopurine. As described earlier 
[28, 30], the Bz derivative was found to be very stable to 
ammonia and for this reason, it is not recommended for 
normal use, although it could be used if the deprotection is 
performed during an extended period of time.  
Table 1. Melting Temperatures (Tm, ºC) of Duplexes Con-
taining 2-aminopurine in 0.1 M Sodium Phosphate 
Buffer. Self-Complemantary Sequence: 5’-CGC 
XAA TTY GCC-3’ 
Sequence (X/Y) pH 5.0
 
pH 6.0 pH 7.0 
B (P/T) 49 52.7 53.4 
C (P/A) 20.5 22.5 25.5 
D (P/C) 24.5 28 25 
E (C/P) 24.5 28.5 27 
 
EXPERIMENTAL SECTION 
 Abbreviations used: ACN: acetonitrile, AcOEt: ethyl 
acetate, Ar: aromatic, CPG: controlled pore glass, DCM: 
dichloromethane, DMAP: N,N-dimethylaminopyridine, 
DMF: N,N-dimethylformamide, DMT: dimethoxytrityl, 
LCAA: long chain amino alkyl, Me : methyl, MeOH: 
methanol, P: 9-(?-D-2'-deoxyfuranosyl)-2-aminopurine, 
THF: tetrahydrofurane. 
 All 1H-, 31P- and 13C-NMR spectra were recorded on a 
Brucker AM 250 spectrometer. Chemical shifts are reported 
in parts per million (?) relative to the internal standard. 13C-
NMR spectral data is reported below with broad-band proton 
noise decoupling; however, assignments were always made 
with the aid of the off-resonance data. 
 DMT-N2-Bz-2-aminopurine-2'-deoxyriboside was pre-
pared from 2'-deoxyguanosine using a multi-step synthesis 
scheme published previously [24-26]. 5'-O-DMT-N2-ibu-2'-
deoxyguanosine was purchased from ChemGenes (USA). 
Chemicals for oligonucleotide synthesis were purchased 
from Perkin Elmer-Applied Biosystems. Anhydrous solvents 
were obtained from Merck (Germany) and SDS (France). 
The rest of the chemicals were from Aldrich (USA) and 
Fluka (Switzeland) and they were used directly without fur-
ther purification. 
General Methods and Standard Work-Up 
 All reactions were carried out in oven-dried glassware, 
under a nitrogen or argon atmosphere, unless specified oth-
erwise. Starting materials were dried by evaporation with the 
dry solvent that will be used for the reaction. Once the reac-
tion was completed, solutions were concentrated to dryness 
and the residues were dissolved in DCM or CHCl3. The re-
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sulting organic solutions were washed with 5% aqueous Na-
HCO3 and saturated aqueous NaCl. The organic phase was 
dried (Na2SO4) and the solvent was removed. 
3',5'-O-N
2
-triisobutyryl-2'-deoxyguanosine 
 2'-Deoxyguanosine (4 g, 14.9 mmol) was dried by coe-
vaporation with anhydrous pyridine. 50 mL of anhydrous 
pyridine and 2.35 g of isobutyric anhydride (14.9 mmol) and 
0.52 g of DMAP (4.26 mmol) were added to the residue. The 
mixture was heated at 50 ˚C overnight. The solution was 
allowed to cool down at room temperature. Then, 30 mL of a 
5% aqueous NaHCO3 solution were added and the mixture 
was stirred for 1 hr at room temperature and concentrated to 
dryness. The residue was dissolved in CHCl3 and washed 
following the standard work-up described above. The prod-
uct was purified by column chromatography (silica gel) 
eluted with a 0-4% MeOH gradient in CHCl3. Yield: 6.55 g 
(13.7 mmol, 92%). TLC (5% MeOH in CHCl3) Rf 0.29. 
1H-
NMR (CDCl3, 500 MHz,): ? 1.14, 1.15, 1.23 (18H, 3s, ibu), 
2.4-2.53 (6H, m, ibu), 2.77 (1H, m, H-2'), 2.99 (1H, m, H-
2''), 4.32 (2H, m, H-5', 5''), 4.70 (1H, m, H-4'), 5.35 (1H, m, 
H-3'), 6,19 (1H, t, H-1'), 7.75 (1H, s, H-8), 9.56 (1H, s, NH-
1), 12.20 (1H, m, NH-CO). 13C-NMR (CDCl3, 75 MHz): ? 
18.7, 18.8 Me ibu), 33.7, 33.8 (CH ibu), 33.6 (CH ibu), 36,6 
(C-2'), 63.3 (C-5'), 74.2 (C-3'), 82.5 (C-1'), 85.6 (C-4'), 
122.34 (C-5), 137.8 (C-8), 147.5 (C-4, C-2), 155.4 (C-6), 
176.1 (CONH), 177.5, 179.0 (COOCH2, COOCH2). 
3',5'-O-N
2
-triisobutyryl-9-(?-D-2'-deoxyfuranosyl)-2-
aminopurine (1) 
 3',5'-O-N2-Triisobutyryl-2'-deoxyguanosine was conver-
ted to 3',5'-O-N2-triisobutyryl-9-(?-D-2'-deoxyfuranosyl)-2-
aminopurine following a similar protocol to the one descri-
bed for the benzoyl derivative [24-26]: 3',5'-O-N2-
triisobutyryl-2'-deoxyguanosine (6.5 g, 13.7 mmol) was re-
acted with 2,4,6-triisopropylbenzenesulfonyl (TPS) chloride 
(27.4 mmol), DMAP (6.85 mmol) and diisopropylethylami-
ne (54.2 mmol) in 85 mL of DCM for 2 hours at room tem-
perature. Then, the solution was concentrated to dryness and 
the desired TPS derivative was isolated from the reaction 
mixture by silica gel chromatography eluted with a 0-5% 
methanol gradient in DCM.  
 Hydrazine hydrate (53.6 mmol) was added to an ice-
cooled solution of the TPS derivative in THF and the mix-
ture was left reacting for 2 hours at room temperature. The 
reaction mixture was concentrated, dissolved in ethyl acetate 
and washed following the standard work-up protocol. The 
hydrazino derivative was isolated in 86% yield by silica gel 
chromatography eluted with a 0-2% MeOH gradient in 
DCM. Finally, the hydrazino derivative (11.2 mmol) was 
dissolved in 250 mL of THF and heated until boiling. Ag2O 
(101.8 mmol) was added to the solution in 3 portions every 
30 min. After completing the addition process, the reaction 
was refluxed for 2 hours. Then, the reaction mixture was 
concentrated to dryness before the work-up. The resulting 
residue was treated with ethyl acetate and 10% NaI aqueous 
solution. The mixture was filtered through Celite and the 
organic phase was decanted. The organic phase was washed 
with 10% NaI followed by 10% sodium thiosulfate and wa-
ter. The product was purified by silica gel chromatography 
eluted with a 0-5% MeOH gradient in DCM. Overall yield: 
6.07 mmol (44% from starting 3',5'-O-N2-triisobutyryl-2'-
deoxyguanosine). TLC (10% MeOH in DCM) Rf 0.4. 1H-
NMR: (CDCl3, 500 MHz): ?? 1.11, 1.17, 1.25 (18H, 3s, Me 
ibu), 2.51-2.63 (3H, m, CH ibu, H-2'), 2.99-3.01 (2H, m, CH 
ibu, H-2''), 4.32-4.44 (3H, m, H-5', 5'', H-4'), 5.42 (1H, m, H-
3'), 6,42 (1H, m, H-1'), 8.14 (1H, s, H-8), 8.96 (1H, s, H-6), 
8.53 (1H, s, NH-1), 12.17 (1H, m, NH-COPh). 13C-NMR 
(CDCl3, 62 MHz): ? 18.7, 19.1 (Me ibu), 33.7 (CH ibu), 35.9 
(CH ibu), 37.2 (C-2'), 63.4 (C-5'), 74.1 (C-3'), 82.8 (C-1'), 
84.7 (C-4'), 131.3 (C-5), 142.8 (C-8), 149.7 (C-6), 150.9 (C-
4), 152.9 (C-2), 176,2, 176,5, 176,6 (CONH, COOCH2, 
COOCH2). 
N
2
-isobutyryl-9-(?-D-2'-deoxyfuranosyl)-2-aminopurine 
(2) 
 To a solution of 3',5'-O-2-N-triisobutyryl-9-(?-D-2'-
deoxyfuranosyl)-2-aminopurine 1 (1.8 g, 3.9 mmol) in anhy-
drous pyridine (45 mL) and MeOH (6 mL) cooled to -20 ˚C, 
5.4 mL of a 2 M solution of NaOH were added. The reaction 
mixture was stirred 30 min at -20 ˚C. After the solution was 
neutralized with Dowex 50w x 4 (pyridinium salt) until pH= 
7. The Dowex was filtered and washed with a solution of 
H2O:pyridine:MeOH (3:1:1). The filtrates were evaporated 
to dryness and the residue was purified on a silica gel col-
umn eluted with a 0-10% MeOH gradient in CHCl3. Yield 
1.13 g (3.5 mmol, 90%). TLC (20% MeOH in DCM) Rf 
0.15. 1H-NMR as described previously [20]. 13C-NMR: 
(CDCl3, 62 MHz): ? 19.6 (Me ibu), 36.8 (CH ibu), 41.1 (C-
2'), 63.0 (C-5'), 72.2 (C-3'), 85.7 (C-1'), 89.3 (C-4'), 132.1 
(C-5), 146.0 (C-8), 149.6 (C-6), 152.9 (C-4), 154.1 (C-2), 
178.4 (CONH). 
5'-O-DMT-N
2
-isobutyryl-2-aminopurine-2'-deoxyriboside-
3'-O-(N,N-diisopropyl)-2-cyanoethyl phosphoramidite (4) 
 N
2-Isobutyryl-9-(?-D-2'-deoxyfuranosyl)-2-amino purine 
2 (1.2 g, 3.7 mmol) was reacted with DMT-Cl in pyridine as 
previously described [20]. 
 DMT-N2-ibu-9-(?-D-2'-deoxyfuranosyl)-2-amino purine 
(3, 860 mg, 2.66 mmol) was reacted with 0.58 mL (2.66 
mmol) of 2-cyanoethoxy-N,N-diisopropylamino chloro-
phosphine in the presence of 1.4 mL (10.64 mmol) of diiso-
propylethylamine as previously described [24-26]. Yield 650 
mg (0.8 mmol, 75%). TLC (1% Et3N in DCM) Rf 0.9. 
31P-
NMR: (CDCl3, 101 MHz): ? 149.1 and 149.8. 
5'-O-Dimethoxytrityl-9-(?-D-2'-deoxyfuranosyl)-2-
aminopurine (5) 
 When the procedure of McLaughlin [24] was performed 
with 5'-O-dimethoxytrityl-N2-ibu-2'-deoxyguanosine the ibu 
group in position 2 was lost during the silver oxidation. 5'-O-
DMT- N2-ibu-2'-deoxyguanosine (2 g, 3.1 mmol) was dis-
solved in DMF and 0.8 mL of hexamethyldisilazane were 
added. After 3 hours of magnetic stirring the mixture was 
concentrated to dryness and residual DMF was eliminated by 
repeated evaporation with toluene. The resulting oil was dis-
solved in 30 mL of DCM and reacted with 2,4,6-
triisopropylbenzenesulfonyl (TPS) chloride (6.2 mmol), 
DMAP (1.55 mmol) and diisopropylethylamine (11.8 mmol) 
for 2 hours at room temperature. The solution was concen-
trated to dryness and the desired TPS derivative was isolated 
from the reaction mixture on a silica gel column eluted with 
a 0-5% MeOH gradient in DCM. Yield 1.64 g (61%). To an 
ice-cooled solution of the TPS derivative in 20 mL of tetra-
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hydrofurane, NH2-NH2.H20 (3.2 mmol) were added and the 
mixture was left overnight at room temperature. The reaction 
mixture was concentrated, dissolved in ethyl acetate and 
washed following the standard work-up protocol. The hy-
drazino derivative was isolated on a 49% yield by silica gel 
chromatography eluted with a 0-15% methanol gradient in 
DCM. Finally, the hydrazino derivative (0.4 g, 0.67 mmol) 
was treated with Ag2O (0.81 mmol) and the mixture was 
refluxed overnight. The reaction mixture was concentrated to 
dryness before work-up. The residue was treated with ethyl 
acetate and a 10% NaI aqueous solution. The mixture was 
filtered through Celite and the organic phase was decanted. 
The organic phase was washed with 10% NaI followed by 
10% sodium thiosulfate and water. The product was purified 
on silica gel chromatography eluted with a 0-10% MeOH 
gradient in DCM. Yield: 120 mg (32%).TLC (10% MeOH in 
DCM) Rf 0.4. 1H-NMR: (CDCl3, 500 MHz): ?? 2.5 (1H, m, 
H-2'), 2.8 (1H, m, H-2''), 3.7 (6H, s, MeO DMT), 4.2 (2H, m, 
H-5'), 4.7 (1H, m, H-4'), 5.2 (1H, m, H-3'), 6,3 (1H, t, H-1'), 
6.7-7.4 (13H, Ar DMT), 8.1 (1H, s, H-6), 8.6 (1H, s, H-8). 
13C-NMR (CDCl3, 62 MHz): ? 39.6 (C-2'), 55.1 (MeO, 
DMT), 63.7 (C-5'), 72.3 (C-3'), 83.7 (C-4'), 86.1 (C-1'), 86.4 
(Cq DMT), 113.1 (DMT), 126.6 (DMT), 128.5 (C-5), 129.9 
(DMT), 135.5 (DMT), 140.7 (C-8), 144.5 (DMT), 149.6 (C-
6), 152.7 (C-4), 158.4 (DMT), 159.6 (C-2). 
5'-O-Dimethoxytrityl-N
2
-dimethylaminomethyliden-9-(?-D-
2'-deoxy-furanosyl)-2-aminopurine (6) 
 Compound 5 (100 mg, 0.22 mmol) was dissolved in 2 
mL of DMF and 0.2 mL (0.24 mmol) of N,N-
dimethylformamide dimethyl acetal were added. After 48 
hours of magnetic stirring, the solution was concentrated to 
dryness with a yield of 120 mg (91%) of the desired product 
that was used in the next step without further purification. 
Attempts of silica gel purification did not yield the desired 
compound. Lost of protecting groups was observed, instead. 
TLC (10% MeOH in DCM) Rf 0.4. 1H-NMR (CDCl3, 250 
MHz): ? 2.59-3.01 (2H, m, H-2'), 3.13 (3H, d, Me dmf), 3.16 
(3H, d, Me dmf), 3.74 (6H, s, MeO DMT), 3.37 (2H, m, H-
5'), 4.20 (1H, m, H-4'), 4.64 (1H, m, H-3'), 6.63 (1H, t, H-1'), 
6.7-7.4 (13H, m, Ar DMT), 8.0 (1H, s, H-6), 8.6 (1H, s, H-
8), 8.8 (1H, m, CH dmf). 13C-NMR (CDCl3, 62 MHz): ? 
34.8 (Me dmf), 40.8 (Me dmf), 41.1 (C2'), 54.9 (Me DMT), 
63.8 (C-5'), 71.6 (C-3'), 83.0 (C-4'), 85.9 (C-1'), 86.2 (Cq 
DMT), 112.9 (DMT), 126.6 (DMT), 129.8 (DMT), 130.2 (C-
5), 135.4 (DMT), 141.3 (C-8), 144.4 (DMT), 148.9 (C-6), 
158.1 (C-2), 158.3 (DMT), 162.6 (CH dmf). 
 Preparation of DMT-N2-protected(Bz, ibu, dmf)-9-(?-D-
2'-deoxyfuranosyl)-2-aminopurine-3'-O-succinyl-LCAA-
CPG supports. 
 DMT-N2-protected(Bz [24], ibu, dmf)-9-(?-D-2'-
deoxyfuranosyl)-2-aminopurine derivatives (0.15 mmol) 
were dissolved in 6 mL of dry DCM. To these solutions 23.2 
mg of DMAP (0.19 mmol) and 19 mg of succinic anhydride 
(0.19 mmol) were added. The mixtures were stirred at room 
temperature overnight. Completeness of the reactions was 
confirmed by careful TLC analysis. Thereafter, the mixtures 
were diluted with DCM and washed with 0.1 M de NaH2PO4 
pH=5. The organic phases were dried and concentrated to 
dryness. The residues were dissolved in DCM and then pre-
cipitated on 50 mL of (1:1) mixture of hexane and ethyl 
ether. N2-Bz derivative: Yield 70%. TLC (5% MeOH in 
CHCl3) Rf 0.35. N
2-ibu derivative: Yield 54%. TLC (5% 
MeOH in CHCl3) Rf 0.35. N
2-dmf derivative: Yield 64%. 
TLC (10% MeOH in DCM) Rf 0.1. 1H- and 13C-NMR con-
firms the addition of the succinyl group. 
 DMT-N2-protected-9-(?-D-2'-deoxyfuranosyl)-2-
aminopurine 3'-O-succinates were reacted with amino-
LCAA-CPG (500 Å, loading 98 μmol/g) supports following 
a previously described protocol [34]. Nucleoside loadings 
were as follows: N2-Bz: 34 μmol/g; N2-ibu: 52 μmol/g; N2-
dmf: 48 μmol/g. 
Oligonucleotide Synthesis and Purification  
 Sequence A: 5’-CGT AGP GAT GC-3’ was prepared on 
a 10 μmol scale and sequences B (P/C): 5’-CGC PAA TTC 
GCG-3’; C (P/A): 5’-CGC PAA TTA GCG-3’; D (P/T): 5’-
CGC PAA TTT GCG-3’; and E (C/P): 5’-CGC CAA TTP 
GCG-3’ were prepared on a 1 μmol scale using the cycles 
implemented by the manufacturer. For the addition of the 
natural bases, commercially available nucleoside phos-
phoramidites protected with the benzoyl (A, C) and isobu-
tyryl (G) groups were used. For the preparation of sequence 
A two comparative 10 μmol-scale synthesis were performed 
using different 2-aminopurine phosphoramidites: the ibu-
protected 2-aminopurine phosphoramidite (4) and the com-
mercially available dmf-protected 2-aminopurine phos-
phoramidite. In all cases the last DMT group was left to help 
purification. Coupling efficiencies were 99%. Sequence: 5’-
TP-3’ was assembled using 35 mg of the supports of the 2-
aminopurine-2'-deoxyriboside containing the ibu and the dmf 
groups and T 2-cyanoethyl phosphoramidite. Syntheses were 
performed using an automatic DNA synthesizer (Applied 
Biosystems Mod.392). 
 Sequences A-E were deprotected using standard proto-
cols. After deprotection, sequences B-E were purified using 
oligonucleotide purification cartridges following the instruc-
tions of the suppliers. Further purification was achieved by 
reversed-phase HPLC. HPLC conditions were as follows: 
Column PRP-1, 10 ?m, (305x8 mm), flow rate 2 mL/min, 30 
min linear gradient from 5% to 40% ACN over 0.1 M aque-
ous triethylammonium acetate pH 6.5. Overall yields were: 
B 41%, C 43%, D 43%, E 38%. Sequence A was purified by 
reversed-phase HPLC using the DMT on / DMT off protocol 
[25]. Column PRP-1, 12-22 ?m, (250x21.5 mm), flow rate 5 
mL/min, DMT on gradient: a 30 min linear gradient from 
18% to 60% ACN over 0.1 M aqueous triethylammonium 
acetate pH 6.5; DMT off gradient: a 30 min linear gradient 
from 5% to 50% ACN over 0.1 M aqueous triethylammo-
nium acetate pH 6.5. After the first HPLC purification 
(DMT-on) the amounts of DMT-oligonucleotide obtained 
were 363 OD (using the ibu group for 2-aminopurine) and 
156 OD (using the dmf group for the 2-aminopurine). After 
the second HPLC (DMT off) 276 OD (ibu) and 111 OD 
(dmf) were obtained. 
 The nucleoside composition of the oligonucleotides car-
rying 2-aminopurine was confirmed by hydrolysis with 
snake venom phosphodiesterase and alkaline phosphatase 
followed by HPLC analysis [20]. The oligonucleotide 5’-
CGC PAA TTC GCG-3’ was further analyzed by mass spec-
trometry (electrospray): found 3629.6 expected for 
C116H147N46O69P11 3629.9. 
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Deprotection Studies for Bz-, ibu- and dmf-protected 2-
aminopurine-2'-deoxyriboside 
 Supports containing 5'-O-DMT-N2-(Bz-, ibu- or dmf)-
protected 2-aminopurine 2'-deoxyriboside were detritylated 
with 3% TCA in DCM. Aliquots of the different supports (5 
mg each) were treated with concentrated ammonia (1 mL) 
and were left at room temperature and 55˚C for different 
periods of time. Then, the solutions were concentrated to 
dryness and analyzed by reverse-phase HPLC. 
Depurination Studies 
 Aliquots of the 5’-TP-3’-succinyl-CPG were treated with 
3% TCA solution in DCM at room temperature for different 
times up to 7 days. The supports were filtered, washed with 
ACN and dried. The resulting supports were treated with 
concentrated ammonia at 55˚C for 2 hours and the solutions 
were concentrated to dryness. The resulting products were 
analyzed by reverse-phase HPLC (see conditions in oligonu-
cleotide synthesis and purification). The depurination prod-
uct eluted 0.5 min after the peak corresponding to the dimer 
containing 2-aminopurine. 5’-TP-3’ dinucleotide: UV (water 
pH 6.5) max 252 (P), 268 (T) and 307 (P) nm; enzyme diges-
tion showed the presence of 2-aminopurine 2'-deoxyriboside 
and thymidine; mass spectra M= 555.3 (expected for 
C20H26N7O10P 555.4). Depurination product. UV (water pH 
6.5) max 270 (T) nm, enzyme digestion showed only the 
presence of thymidine, mass spectra M= 438 (expected for 
C15H23N2O11P 438.3). 
Melting Studies 
 Oligonucleotides P/C, P/A, P/T and C/P were dissolved 
in a solution of 0.1 M sodium phosphate buffer at different 
pHs. The solutions were heated at 80˚C and allowed to cool 
slowly to 4˚C. UV absorption spectra and melting experi-
ments (absorbance vs temperature) were recorded in 1 cm 
path-length cells with a spectrophotometer, which has a tem-
perature controller with a programmed temperature increase 
of 0.5 deg min-1. Thermal denaturation curves were run on 
duplex concentration of 4 ?M at 260 nm. 
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